Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.72 +1.13%

+$0.32 today

Market cap
$144.76M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.24M

Average 0.28M

Income Statement

Follow revenue through to earnings.

Revenue

$102.48M

FY 2025 · Annual

+65.2% YoY

Operating Income

-$104.95M

FY 2025 · Annual

Net Income

-$191.09M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

STRO Earnings Waterfall · TTM

NASDAQ:STRO · Revenue to Net Income

Key Ratios

EPS$-307.72
Gross Margin97.8%
Net Margin-317.8%
P/E Ratio-0.5
P/S Ratio4.3

Analysis

$99.6M of revenue converted into -$153.6M of net income for the selected period. Gross margin is 97.8% and net margin is -317.8%, showing how much revenue survives after costs and taxes. EPS is $-307.72, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingNov 9, 2026
4Statement of changes in beneficial ownershipSep 22, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does STRO generate?

Sutro Biopharma, Inc. (STRO) reported $102.48M of revenue in fiscal 2025.

Is STRO profitable?

Sutro Biopharma, Inc. (STRO) reported -$191.09M of net income, with a net margin of -186.5%.